Stocktoria
UNITED THERAPEUTICS Corp UTHR
UNITED THERAPEUTICS Corp (UTHR) earns a Piotroski F-score of 7/9 (strong financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $3.2B at a 41.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.29 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-06 | RBC Capital | Outperform (main) |
| 2026-07-23 | JP Morgan | Overweight (main) |
| 2026-07-10 | B of A Securities | Neutral (main) |
| 2026-07-07 | RBC Capital | Outperform (main) |
| 2026-05-07 | RBC Capital | Outperform (main) |
| 2026-05-07 | Wells Fargo | Overweight (up) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 7/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.399 |
| Retained earnings / assets | 1.086 |
| EBIT / assets | 0.189 |
| Equity / liabilities | 9.054 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| UTHR | UNITED THERAPEUTICS Corp | 7/9 | 16.93 | 17.4 | +10.6% |
| BMRN | BIOMARIN PHARMACEUTICAL INC | 4/9 | 7.43 | 32.7 | +12.9% |
| AMRX | Amneal Pharmaceuticals, Inc. | 7/9 | 2.06 | 76.3 | +8% |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | 5/9 | -0.11 | 124 | +65.2% |
| SRPT | Sarepta Therapeutics, Inc. | 4/9 | -2.78 | — | +15.6% |
| PRGO | PERRIGO Co plc | 4/9 | -0.37 | — | -2.8% |
| JAZZ | Jazz Pharmaceuticals plc | 5/9 | 1.63 | — | +4.9% |
About UNITED THERAPEUTICS Corp
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
FAQ
Is UTHR financially healthy?
UNITED THERAPEUTICS Corp's Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does UTHR pay a dividend?
No, UNITED THERAPEUTICS Corp does not currently pay a dividend.
How profitable is UTHR?
In FY2025, UNITED THERAPEUTICS Corp had a net margin of 41.9% and a return on equity of 18.8%.
Is UTHR overvalued or undervalued?
UNITED THERAPEUTICS Corp trades at about 18.4× trailing earnings — above its 10-year norm (10-year range 8.6×–20.1×, median 14.2×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for UTHR?
The average Wall-Street price target for UNITED THERAPEUTICS Corp is $653.23, about 27.7% above the recent price, from 13 analysts (consensus: buy).
Is UTHR a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on UNITED THERAPEUTICS Corp: a Piotroski F-score of 7/9, an Altman Z″ in the safe zone, a P/E of about 17.4×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.